In this issue:
- First-line atezolizumab/ vemurafenib/cobimetinib for unresectable BRAF V600+ve melanoma
- Anti-PD1 checkpoint inhibitors for acral melanoma
- Nivolumab vs. everolimus in advanced renal cell carcinoma
- Predicting outcomes and immune-related adverse events in PD1 inhibitor-treated advanced NSCLC
- Outcomes associated with immune-related adverse events in nivolumab-treated metastatic NSCLC
- Toxicities, body composition and QOL after anti-PD1/PD-L1 therapy
- Sarcomatoid renal cell carcinoma: redefining first-line treatment
- Neoadjuvant nivolumab for resectable Merkel cell carcinoma
- Combined PD-L1 and CTLA-4 inhibition for CRC
- Immune checkpoint inhibitor rechallenge after immunerelated adverse events
Download PDF